By Katherine Hamilton

Precigen shares rose after the company notched its first drug sale in the fourth quarter.

The stock rose 19% to $3.70 in after-hours trading Wednesday. Through the close, shares had gained 93% over the past three months.

The biopharmaceutical company's drug Papzimeos, which is approved for adults with recurrent respiratory papillomatosis, generated $3.4 million in net product revenue.

That reflected the first partial quarter of U.S. commercial sales, as payer policies came into effect.

Precigen said its launch in the U.S. is building momentum with increasing demand in the current first quarter.

"2025 marked a transformational year for Precigen as we transitioned from a clinical-stage to a commercial-stage company and recognized our first commercial product revenues toward the end of the year," Chief Executive Helen Sabzevari said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

March 25, 2026 18:09 ET (22:09 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.